生物银行市场规模、份额和成长分析（按产品和服务、生物银行类型、样本类型、储存类型、所有者、应用、最终用户和地区）—产业预测 2025-2032

2023 年生物银行市场规模价值 720 亿美元，预计将从 2024 年的 769 亿美元成长到 2032 年的 1,301.6 亿美元，预测期内（2025-2032 年）的复合年增长率为 6.8%。

生物银行市场正在经历显着的成长，这得益于先进技术、资料分析和自动化，这些技术正在将传统的生物银行转变为创新的虚拟平台。这种转变迎合了不同类型的生物库，如疾病特异性生物库、人类生物库、组织库和血库，从而增强了市场动态。退化性疾病的日益普及将进一步增加对生物银行服务的需求。向虚拟生物库的转变将简化流程，减少週转时间，使研究人员能够更有效率地工作，并最终提高生物库的产生收入。此外，软体公司正在积极开发解决方案以优化生物银行流程，支援虚拟系统的广泛采用。技术和需求的整合将在未来几年推动生物银行市场的显着成长。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

生物库市场规模（依产品/服务及复合年增长率） (2025-2032)

• 市场概况
• 装置
  • 储存设施
  • 样品分析设备
  • 样品处理设备
  • 样品输送装置
• 耗材
  • 储存耗材
  • 分析耗材
  • 加工耗材
  • 收集耗材
• 服务
  • 储存服务
  • 加工服务
  • 运输服务
  • 供应服务
• 软体

生物库市场规模（按生物库类型和复合年增长率） (2025-2032)

• 市场概况
• 实体/真实生物库
• 组织生物库
• 基于人群的生物库
• 遗传学（DNA/RNA）
• 基于疾病的生物库
• 虚拟生物库

生物库市场规模（按样本类型和复合年增长率） (2025-2032)

• 市场概况
• 血液製品
• 人体组织
• 细胞株
• 核酸
• 体液
• 人类排泄物

生物库市场规模（按储存类型和复合年增长率） (2025-2032)

• 市场概况
• 手动储存
• 自动储存

生物库市场规模（按所有权和复合年增长率） (2025-2032)

• 市场概况
• 大学
• 国家/地区机构
• 非营利组织
• 私人组织

生物库市场规模（按应用和复合年增长率） (2025-2032)

• 市场概况
• 再生医学
• 生命科学研究
• 临床研究

生物库市场规模（按最终用户和复合年增长率） (2025-2032)

• 市场概况
• 药品
• 生技公司和 CRO
• 学术的
• 研究组织
• 医院

生物库市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司详细信息
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Thermo Fisher Scientific Inc.（United States）
• Merck KGaA（Germany）
• QIAGEN NV（Netherlands）
• Hamilton Company（United States）
• Tecan Trading AG（Switzerland）
• Becton, Dickinson and Company（BD）（United States）
• Lonza Group AG（Switzerland）
• Charles River Laboratories International, Inc.（United States）
• BioLife Solutions, Inc.（United States）
• Brooks Automation, Inc.（United States）
• Greiner Bio-One International GmbH（Austria）
• STEMCELL Technologies Inc.（Canada）
• Chart Industries, Inc.（United States）
• BioIVT（United States）
• Firalis SA（France）
• Celltex Therapeutics Corporation（United States）
• Sigma-Aldrich Corporation（United States）
• Hope Biosciences（United States）
• 54Gene（Nigeria）

结论和建议

Biobanking Market size was valued at USD 72.0 billion in 2023 and is poised to grow from USD 76.9 billion in 2024 to USD 130.16 billion by 2032, growing at a CAGR of 6.8% during the forecast period (2025-2032).

The Biobanking Market is experiencing significant growth, fueled by advanced technologies, data analytics, and automation that are evolving traditional biobanks into innovative virtual platforms. This transformation accommodates various types of biobanks, including disease-specific, human-based, tissue, and blood banks, which collectively strengthen market dynamics. Increasing prevalence of degenerative diseases further enhances the demand for biobanking services. The shift towards virtual biobanking streamlines processes, reducing turnaround times and allowing researchers to work more efficiently, ultimately enhancing revenue generation for biobanks. Additionally, software companies are actively developing solutions to optimize the biobanking process, supporting the widespread adoption of virtual systems. This convergence of technology and demand positions the Biobanking Market for substantial growth in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Biobanking market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Biobanking Market Segments Analysis

Global Biobanking Market is segmented by Product &Service, Biobanks Type, Sample Type, Storage Type, Ownership, Application, End user and region. Based on Product &Service, the market is segmented into Equipment, Consumables, Services and Software. Based on Biobanks Type, the market is segmented into Physical/Real Biobanks, Tissue Biobanks, Population Based Biobanks, Genetic (DNA/RNA), Disease Based Biobanks and Virtual Biobanks. Based on Sample Type, the market is segmented into Blood Products, Human Tissues, Cell Lines, Nucleic Acids, Biological Fluids and Human Waste Products. Based on Storage Type, the market is segmented into Manual Storage and Automated Storage. Based on Ownership, the market is segmented into Universities, National/Regional Agencies, Non-Profit Organizations and Private Organizations. Based on Application, the market is segmented into Regenerative Medicine, Life Science Research and Clinical Research. Based on End user, the market is segmented into Pharmaceutical, Biotechnology Companies and CROs, Academic, Research Institutes and Hospitals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Biobanking Market

One of the primary catalysts for the biobanking market is the swift advancement in genomics research and the rise of personalized medicine. As researchers deepen their comprehension of genetic markers and the intricacies of disease progression, the necessity for biobanks that preserve high-quality biosamples for genomic studies becomes increasingly prominent. These biosamples are crucial for the development of targeted therapies, which are essential in the realm of personalized medicine. Consequently, biobanking plays a pivotal role in shaping the future of healthcare, highlighting its significance in supporting cutting-edge research and innovative treatment strategies tailored to individual patients.

Restraints in the Biobanking Market

The biobanking market faces significant constraints stemming from ethical and legal considerations related to the collection, storage, and utilization of biospecimens. Key concerns include patient privacy, the processes of obtaining informed consent, and the potential for sensitive information to be misappropriated. These challenges create obstacles for biobanks as they strive to navigate regulatory requirements while maintaining public trust. The necessity to balance operational goals with the protection of individual rights and data confidentiality can hinder the growth and development of biobanks, as they must work within a complex legal landscape while ensuring ethical standards are upheld.

Market Trends of the Biobanking Market

The biobanking market is witnessing a significant trend towards the integration of artificial intelligence (AI) and big data analytics, revolutionizing how biosamples are managed and utilized. This technological advancement enhances specimen tracking, streamlines data management, and ensures superior quality in specimen storage. By employing AI-driven analytics, biobanks can sift through extensive biosample datasets to uncover valuable patterns and insights, thereby accelerating biomarker discovery and expediting drug development timelines. As researchers increasingly leverage these tools, the biobanking sector is positioned to unlock new opportunities in personalized medicine and innovation, ultimately driving growth and evolution within the healthcare landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Biobanking Market Size by Product &Service & CAGR (2025-2032)

• Market Overview
• Equipment
  • Storage Equipment
  • Sample Analysis Equipment
  • Sample Processing Equipment
  • Sample Transport Equipment
• Consumables
  • Storage Consumables
  • Analysis Consumables
  • Processing Consumables
  • Collection Consumables
• Services
  • Storage Services
  • Processing Services
  • Transport Services
  • Supply Services
• Software

Global Biobanking Market Size by Biobanks Type & CAGR (2025-2032)

• Market Overview
• Physical/Real Biobanks
• Tissue Biobanks
• Population Based Biobanks
• Genetic (DNA/RNA)
• Disease Based Biobanks
• Virtual Biobanks

Global Biobanking Market Size by Sample Type & CAGR (2025-2032)

• Market Overview
• Blood Products
• Human Tissues
• Cell Lines
• Nucleic Acids
• Biological Fluids
• Human Waste Products

Global Biobanking Market Size by Storage Type & CAGR (2025-2032)

• Market Overview
• Manual Storage
• Automated Storage

Global Biobanking Market Size by Ownership & CAGR (2025-2032)

• Market Overview
• Universities
• National/Regional Agencies
• Non-Profit Organizations
• Private Organizations

Global Biobanking Market Size by Application & CAGR (2025-2032)

• Market Overview
• Regenerative Medicine
• Life Science Research
• Clinical Research

Global Biobanking Market Size by End user & CAGR (2025-2032)

• Market Overview
• Pharmaceutical
• Biotechnology Companies and CROs
• Academic
• Research Institutes
• Hospitals

Global Biobanking Market Size & CAGR (2025-2032)

• North America (Product &Service, Biobanks Type, Sample Type, Storage Type, Ownership, Application, End user)
  • US
  • Canada
• Europe (Product &Service, Biobanks Type, Sample Type, Storage Type, Ownership, Application, End user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product &Service, Biobanks Type, Sample Type, Storage Type, Ownership, Application, End user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product &Service, Biobanks Type, Sample Type, Storage Type, Ownership, Application, End user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product &Service, Biobanks Type, Sample Type, Storage Type, Ownership, Application, End user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Thermo Fisher Scientific Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hamilton Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tecan Trading AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Group AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories International, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioLife Solutions, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Brooks Automation, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Greiner Bio-One International GmbH (Austria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• STEMCELL Technologies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chart Industries, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioIVT (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Firalis S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celltex Therapeutics Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sigma-Aldrich Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hope Biosciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• 54Gene (Nigeria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations